Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 6391Neoplasms 5364Prostatic Neoplasms 2966Carcinoma, Non-Small-Cell Lung 2708Colorectal Neoplasms 2678Lung Neoplasms 2267Multiple Myeloma 1663Lymphoma 1600Neoplasm Metastasis 1551Leukemia, Myeloid, Acute 1539Melanoma 1486Pancreatic Neoplasms 1470Ovarian Neoplasms 1423Leukemia 1389Head and Neck Neoplasms 1284Precursor Cell Lymphoblastic Leukemia-Lymphoma 1282Lymphoma, Non-Hodgkin 1231Colonic Neoplasms 1159Carcinoma, Hepatocellular 1142Stomach Neoplasms 1127Leukemia, Lymphocytic, Chronic, B-Cell 1090Brain Neoplasms 1050Rectal Neoplasms 980Lymphoma, Follicular 979Recurrence 975Uterine Cervical Neoplasms 926Glioblastoma 920Carcinoma, Renal Cell 882Lymphoma, Large B-Cell, Diffuse 853Hodgkin Disease 777

Interventions

masitinib 1Tyrosine Kinase Inhibitors 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Gastro Intestinal Stromal Tumor × Clear all
NCT03963544 2025-12-10

METAGIST

Institut Bergonié

Completed
492 enrolled 7 charts

Gastro Intestinal Stromal Tumor

NCT01506336 2018-12-11

Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

AB Science

Phase 2 Completed
44 enrolled

Gastro Intestinal Stromal Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡